Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced its participation in the Lytham Partners Summer 2021 Investor Conference from June 14-16, 2021. The company will present on June 14, starting at 3:30 PM ET. Interested parties can access the webcast here. Lipocine focuses on metabolic and endocrine disorders, with notable products in its pipeline including TLANDO and LPCN 1144, aimed at treating testosterone deficiencies and non-cirrhotic NASH, respectively.
- None.
- None.
SALT LAKE CITY, June 7, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference. The conference will be held virtually. Presentation details are below.
Lytham Partners Summer 2021 Investor Conference June 14-16
Presentation time: | June 14, 2021 starting at 3:30 PM ET |
Webcast link: |
The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
About Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-lytham-partners-summer-2021-investor-conference-301306384.html
SOURCE Lipocine Inc.
FAQ
When is Lipocine's presentation at the Lytham Partners Summer 2021 Investor Conference?
How can I access Lipocine's presentation webcast?
What is Lipocine's main focus as a biopharmaceutical company?
What are the notable products in Lipocine's pipeline?
What condition does TLANDO aim to treat?
